10-K Filing

Processa Pharmaceuticals, Inc. CIK: 1533743 FY 2019

Filing Information

Form Type	10-K
Accession Number	`0001493152-20-003534`
Period End Date	20191231
Filing Date	20200306
Fiscal Year	2019
Fiscal Period	FY
XBRL Instance	pcsa-20191231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 76 Income Statement 21 Cash Flow Statement 85 Stockholders Equity 22

Balance Sheet 76 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	350.00M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	5.49M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.74M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$691.54K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	5.53M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	5.53M	shares	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	-	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	5.49M	shares	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	$21.58K	USD	Point-in-time
Common stock, shares deemed dividend payable	`CommonStockSharesDeemedDividendPayable`	28,971.00	shares	Point-in-time
Common stock, shares deemed dividend payable	`CommonStockSharesDeemedDividendPayable`	-	shares	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$257.83K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$315.61K	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$1.01M	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$2.02M	USD	Point-in-time
Software	`CapitalizedComputerSoftwareGross`	$19.74K	USD	Point-in-time
Software	`CapitalizedComputerSoftwareGross`	$19.74K	USD	Point-in-time
Office equipment	`MachineryAndEquipmentGross`	$9.33K	USD	Point-in-time
Office equipment	`MachineryAndEquipmentGross`	$9.33K	USD	Point-in-time
Total Cost	`PropertyPlantAndEquipmentGross`	$29.07K	USD	Point-in-time
Total Cost	`PropertyPlantAndEquipmentGross`	$29.07K	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$11.69K	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$20.14K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$17.38K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$8.93K	USD	Point-in-time
Operating lease right-of-use assets, net of accumulated amortization	`OperatingLeaseRightOfUseAsset`	$219.07K	USD	Point-in-time
Operating lease right-of-use assets, net of accumulated amortization	`OperatingLeaseRightOfUseAsset`	-	USD	Point-in-time
Intangible assets, net of accumulated amortization	`IntangibleAssetsNetExcludingGoodwill`	$9.64M	USD	Point-in-time
Intangible assets, net of accumulated amortization	`IntangibleAssetsNetExcludingGoodwill`	$10.44M	USD	Point-in-time
Security deposit	`SecurityDeposit`	$5.54K	USD	Point-in-time
Security deposit	`SecurityDeposit`	$5.54K	USD	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$9.87M	USD	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$10.44M	USD	Point-in-time
Total Assets	`Assets`	$12.48M	USD	Point-in-time
Total Assets	`Assets`	$10.88M	USD	Point-in-time
Senior convertible notes, net of debt issuance costs	`SeniorNotesCurrent`	$802.50K	USD	Point-in-time
Senior convertible notes, net of debt issuance costs	`SeniorNotesCurrent`	$230.00K	USD	Point-in-time
Current maturities of operating lease liability	`OperatingLeaseLiabilityCurrent`	-	USD	Point-in-time
Current maturities of operating lease liability	`OperatingLeaseLiabilityCurrent`	$77.99K	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$20.34K	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$21.90K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$75.61K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$292.10K	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	-	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	$316.00	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$103.26K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$213.24K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$1.19M	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$645.70K	USD	Point-in-time
Non-current operating lease liability	`OperatingLeaseLiabilityNoncurrent`	-	USD	Point-in-time
Non-current operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$147.39K	USD	Point-in-time
Net deferred tax liability	`DeferredIncomeTaxLiabilitiesNet`	$1.53M	USD	Point-in-time
Net deferred tax liability	`DeferredIncomeTaxLiabilitiesNet`	$2.13M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.78M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.87M	USD	Point-in-time
Commitments and Contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, par value $0.0001, 100,000,000 and 350,000,000 shares authorized; 5,486,476 and 5,525,009 issued and outstanding at December 31, 2019 and 2018, respectively	`CommonStockValue`	$549.00	USD	Point-in-time
Common stock, par value $0.0001, 100,000,000 and 350,000,000 shares authorized; 5,486,476 and 5,525,009 issued and outstanding at December 31, 2019 and 2018, respectively	`CommonStockValue`	$552.00	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$19.12M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$18.99M	USD	Point-in-time
Common stock deemed dividend payable: 28,971 shares at par value	`CommonStockDeemedDividendPayable`	-	USD	Point-in-time
Common stock deemed dividend payable: 28,971 shares at par value	`CommonStockDeemedDividendPayable`	$3.00	USD	Point-in-time
Stock subscription receivable	`CommonStockSharesSubscriptions`	-	USD	Point-in-time
Stock subscription receivable	`CommonStockSharesSubscriptions`	$1.80M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-7.62M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.98M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$373.16K	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$8.01M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$9.70M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$10.88M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$12.48M	USD	Point-in-time

Income Statement 21 line items

Line Item	Tag	Value	Unit	Period
Research and development expenses	`ResearchAndDevelopmentExpense`	$3.09M	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpense`	$2.32M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.44M	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.61M	USD	Annual
Operating Loss	`OperatingIncomeLoss`	$-3.94M	USD	Annual
Operating Loss	`OperatingIncomeLoss`	$-4.52M	USD	Annual
Interest expense	`InterestExpense`	$36.66K	USD	Annual
Interest expense	`InterestExpense`	$161.21K	USD	Annual
Interest income	`InvestmentIncomeInterest`	$18.30K	USD	Annual
Interest income	`InvestmentIncomeInterest`	$11.55K	USD	Annual
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-4.67M	USD	Annual
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-3.96M	USD	Annual
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$258.58K	USD	Annual
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$-902.80K	USD	Annual
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$-602.72K	USD	Annual
Net Loss	`NetIncomeLoss`	$-3.36M	USD	Annual
Net Loss	`NetIncomeLoss`	$-3.77M	USD	Annual
Net Loss Per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.71	USD	Annual
Net Loss Per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.70	USD	Annual
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.33M	shares	Annual
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.53M	shares	Annual

Cash Flow Statement 85 line items

Line Item	Tag	Value	Unit	Period
Common stock, shares transferred	`CommonStockSharesTransferred`	-	shares	Annual
Common stock, shares transferred	`CommonStockSharesTransferred`	2.09M	shares	Annual
Conversion of senior convertible debt, value	`ConversionOfSeniorConvertibleDebtValue`	$230.00K	USD	Annual
Net Loss	`NetIncomeLoss`	$-3.36M	USD	Annual
Net Loss	`NetIncomeLoss`	$-3.77M	USD	Annual
Conversion of senior convertible debt, value	`ConversionOfSeniorConvertibleDebtValue`	$2.35M	USD	Annual
Accrued interest	`InterestPayableCurrentAndNoncurrent`	$114.33K	USD	Point-in-time
Accrued interest	`InterestPayableCurrentAndNoncurrent`	$28.93K	USD	Point-in-time
Accrued interest converted into shares of common stock and warrants	`AccruedInterestConvertedIntoSharesOfCommonStockAndWarrants`	172,327.00	shares	Annual
Depreciation	`Depreciation`	$8.45K	USD	Annual
Accrued interest converted into shares of common stock and warrants	`AccruedInterestConvertedIntoSharesOfCommonStockAndWarrants`	18,107.00	shares	Annual
Depreciation	`Depreciation`	$8.45K	USD	Annual
Non-cash lease expense for right-of-use assets	`OperatingLeaseExpense`	$74.12K	USD	Annual
Non-cash lease expense for right-of-use assets	`OperatingLeaseExpense`	-	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	$67.07K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCostsAndDiscounts`	$1.78K	USD	Annual
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$795.33K	USD	Annual
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$621.65K	USD	Annual
Deferred income tax (benefit) expense	`DeferredIncomeTaxExpenseBenefit`	$-602.72K	USD	Annual
Deferred income tax (benefit) expense	`DeferredIncomeTaxExpenseBenefit`	$-902.80K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$510.48K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$74.06K	USD	Annual
Prepaid expenses and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-57.77K	USD	Annual
Prepaid expenses and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-216.39K	USD	Annual
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	-	USD	Annual
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$77.78K	USD	Annual
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$30.49K	USD	Annual
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$94.12K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-216.49K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$241.42K	USD	Annual
Due from related parties	`IncreaseDecreaseInDueFromRelatedParties`	$21.90K	USD	Annual
Due from related parties	`IncreaseDecreaseInDueFromRelatedParties`	$40.69K	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$119.94K	USD	Annual
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$28.87K	USD	Annual
Net cash (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-3.71M	USD	Annual
Net cash (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.75M	USD	Annual
Purchase of software license	`PaymentsToAcquireSoftware`	-	USD	Annual
Purchase of software license	`PaymentsToAcquireSoftware`	$20.50K	USD	Annual
Purchase of intangible asset	`PaymentsToAcquireIntangibleAssets`	-	USD	Annual
Purchase of intangible asset	`PaymentsToAcquireIntangibleAssets`	$1.78K	USD	Annual
Net cash (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-22.28K	USD	Annual
Net cash (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	-	USD	Annual
Net proceeds from issuance of stock	`ProceedsFromIssuanceOfCommonStock`	$2.87M	USD	Annual
Net proceeds from issuance of stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from issuance of senior convertible notes	`ProceedsFromConvertibleDebt`	-	USD	Annual
Proceeds from issuance of senior convertible notes	`ProceedsFromConvertibleDebt`	$805.00K	USD	Annual
Proceeds received in satisfaction of stock subscription receivable	`ProceedsFromIssuanceSubscriptionReceivable`	$900.00K	USD	Annual
Proceeds received in satisfaction of stock subscription receivable	`ProceedsFromIssuanceSubscriptionReceivable`	-	USD	Annual
Transaction costs incurred on senior convertible notes	`PaymentsOfDebtIssuanceCosts`	$82.50K	USD	Annual
Transaction costs incurred on senior convertible notes	`PaymentsOfDebtIssuanceCosts`	$4.28K	USD	Annual
Payment of placement agent and legal fees associated with clinical funding commitment	`ProceedsFromPaymentsForOtherFinancingActivities`	-	USD	Annual
Payment of placement agent and legal fees associated with clinical funding commitment	`ProceedsFromPaymentsForOtherFinancingActivities`	$-168.46K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$1.70M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.62M	USD	Annual
Net (Decrease)/Increase in Cash and Cash Equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.11M	USD	Annual
Net (Decrease)/Increase in Cash and Cash Equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.05M	USD	Annual
Cash and Cash Equivalents - Beginning of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.85M	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.74M	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$691.54K	USD	Point-in-time
Cash and Cash Equivalents - End of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$2.85M	USD	Point-in-time
Cash and Cash Equivalents - End of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.74M	USD	Point-in-time
Cash and Cash Equivalents - End of Year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$691.54K	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Cash paid for interest	`InterestPaidNet`	-	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	-	USD	Annual
Cash paid for income taxes	`IncomeTaxesPaidNet`	-	USD	Annual
Right-of-use asset obtained in exchange for operating lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	-	USD	Annual
Right-of-use asset obtained in exchange for operating lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$293.20K	USD	Annual
Reduction in deferred lease liability	`ReductionInDeferredLeaseLiability`	$-9.96K	USD	Annual
Reduction in deferred lease liability	`ReductionInDeferredLeaseLiability`	-	USD	Annual
Operating lease liability	`OperatingLeaseLiabilities`	$303.16K	USD	Annual
Net	`NonCashleaseLiabilityNet`	-	USD	Annual
Net	`NonCashleaseLiabilityNet`	-	USD	Annual
Recognize exclusive license intangible asset acquired from CoNCERT	`RecognizeExclusiveLicenseIntangibleAssetAcquired`	-	USD	Annual
Recognize exclusive license intangible asset acquired from CoNCERT	`RecognizeExclusiveLicenseIntangibleAssetAcquired`	$-11.04M	USD	Annual
Recognize deferred tax liability for basis difference of Intangible asset	`RecognizationOfDeferredTaxLiability`	-	USD	Annual
Recognize deferred tax liability for basis difference of Intangible asset	`RecognizationOfDeferredTaxLiability`	$3.04M	USD	Annual
Recognize additional paid-in capital for consideration paid from the transfer of 298,615 common shares of Processa released by Promet to CoNCERT for Processa	`PaymentOfAdditionalPaidInCapitalForConsideration`	$8.00M	USD	Annual
Recognize additional paid-in capital for consideration paid from the transfer of 298,615 common shares of Processa released by Promet to CoNCERT for Processa	`PaymentOfAdditionalPaidInCapitalForConsideration`	-	USD	Annual
Cash paid for intangible asset acquired from CoNCERT	`CashPaidForIntangibleAssetAcquiredFromConcert`	-	USD	Annual
Cash paid for intangible asset acquired from CoNCERT	`CashPaidForIntangibleAssetAcquiredFromConcert`	-	USD	Annual
Conversion of $230,000 and $2,350,000, respectively, of Senior Convertible Debt and related accrued interest of $28,930 and $114,333, respectively, into 18,107 and 172,327 shares, respectively, of common stock and warrants	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStockAndWarrants`	$258.93K	USD	Annual
Conversion of $230,000 and $2,350,000, respectively, of Senior Convertible Debt and related accrued interest of $28,930 and $114,333, respectively, into 18,107 and 172,327 shares, respectively, of common stock and warrants	`ConversionOfSeniorConvertibleDebtAndRelatedAccruedInterestIntoSharesOfCommonStockAndWarrants`	$2.46M	USD	Annual
Common stock and stock purchase warrants (forfeited)/issued in connection with a clinical trial funding commitment	`CommonStockAndStockPurchaseWarrantsForfeitedIssuedInConnectionWithClinicalTrialFundingCommitment`	$-900.00K	USD	Annual
Common stock and stock purchase warrants (forfeited)/issued in connection with a clinical trial funding commitment	`CommonStockAndStockPurchaseWarrantsForfeitedIssuedInConnectionWithClinicalTrialFundingCommitment`	$1.80M	USD	Annual

Stockholders Equity 22 line items

Line Item	Tag	Value	Unit	Period
Common stock, shares exchanged	`CommonStockSharesExchanged`	298,615.00	shares	Annual
Conversion of senior convertible notes, costs	`ConversionOfSeniorConvertibleNotesNetOfCosts`	$82.50K	USD	Annual
Issuance of common stock units for cash, cost	`PaymentsOfStockIssuanceCosts`	$308.83K	USD	Annual
Issuance of common stock units for a future research funding commitment, cost	`IssuanceOfCommonStockUnitsForFutureResearchFundingCommitmentCost`	$168.46K	USD	Annual
Balance	`StockholdersEquity`	$373.16K	USD	Point-in-time
Balance	`StockholdersEquity`	$8.01M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.70M	USD	Point-in-time
Recognize the fair value of exclusive license intangible asset acquired from CoNCERT in exchange for 298,615 common shares of Processa held by Promet	`AdjustmentsToAdditionalPaidInCapitalOther`	$8.00M	USD	Annual
Conversion of Senior convertible notes and accrued interest for common stock and stock purchase warrants, net of costs of $82,502	`StockIssuedDuringPeriodValueConversionOfUnits`	$258.93K	USD	Annual
Conversion of Senior convertible notes and accrued interest for common stock and stock purchase warrants, net of costs of $82,502	`StockIssuedDuringPeriodValueConversionOfUnits`	$2.31M	USD	Annual
Issuance of common stock units for cash, net of costs of $308,830	`StockIssuedDuringPeriodValueNewIssues`	$2.87M	USD	Annual
Issuance of common stock units for a future research funding commitment, net of costs of $168,457	`StockIssuedDuringPeriodValueOther`	$-168.46K	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$74.06K	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$510.48K	USD	Annual
Payments made by investor for clinical trial costs	`AdjustmentsToAdditionalPaidInCapitalPaymentMadeByInvestorForClinicalTrialCosts`	$900.00K	USD	Annual
Pledged shares of common stock forfeited upon revised research funding commitment	`PledgeSharesOfCommonStockForfeitedUponRevisedResearchFundingCommitment`	-	USD	Annual
Deemed stock dividend due to full ratched anti-dilution adjustment	`StockIssuedDuringPeriodValueStockDividend`	-	USD	Annual
Net loss	`NetIncomeLoss`	$-3.36M	USD	Annual
Net loss	`NetIncomeLoss`	$-3.77M	USD	Annual
Balance	`StockholdersEquity`	$373.16K	USD	Point-in-time
Balance	`StockholdersEquity`	$8.01M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.70M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.